



PHOSPHAGENICS

ASX Limited

Market Announcements Office

Phosphagenics – Appendix 4D Report and Financial Report for Half-Year ended 30 June 2014

27 August 2014, Melbourne: Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) today releases its consolidated Appendix 4D Report and incorporating the audited Financial Report for the half-year ended 30 June 2014, a copy of which is attached for release to the market.

ENDS

Enquiries

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

Anna Legg
Chief Financial Officer
Phosphagenics Limited
+61 3 9565 1119

About Phosphagenics

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM[®] (Targeted Penetration Matrix). TPM[®] is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

Inherent Risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

Forward-looking Statements

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

www.phosphagenics.com
www.bioelixia.com

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: www.phosphagenics.com Email: info@phosphagenics.com

Appendix 4D

PHOSPHAGENICS LIMITED

ABN 32 056 482 403

Half Year Report Period Ended 30 June 2014

(Previous Corresponding Period: Half year ended 30 June 2013)

The Appendix 4D should be read in conjunction with the most recent Financial Report

Results for announcement to the market

		\$A'000	\$A'000
		6 months 30 June 2014	6 months 30 June 2013
Revenues from ordinary activities	(Down 23%)	712	929
(Loss) from ordinary activities after tax attributable to members	(Down 54%)	(2,785)	(6,072)
Net (Loss) for the period attributable to members	(Down 54%)	(2,785)	(6,072)

Brief explanation of any figures reported above:

Refer Director's Report for explanations

Dividends per ordinary share paid or to be paid:

	Amount per security	Franked amount per security
6 months ended 30 June 2014	-	N/A ¢
6 months ended 30 June 2013	-	N/A ¢
Record date for determining entitlements to the dividend	N/A	

Net Tangible Assets Per Security:

30 June 2014	30 June 2013
1.18 Cents	1.69 Cents